Atlas Trials

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Clinical trial NCT04612894 · UNKNOWN

Trial details

NCT number
NCT04612894
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Thyroid Cancer
Start date
2020-12-01
Primary completion
2022-12-01
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.